Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
An‐Ping Shi, Xiyang Tang, Yanlu Xiong, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

LAG-3 as the third checkpoint inhibitor
Vaishali Aggarwal, Creg J. Workman, Dario A.A. Vignali
Nature Immunology (2023) Vol. 24, Iss. 9, pp. 1415-1422
Open Access | Times Cited: 150
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
Jin-Ling Huo, Yatao Wang, Wen-Jia Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 100
Recurrent or primary metastatic cervical cancer: current and future treatments
Christine Gennigens, Guy Jérusalem, L. Lapaille, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100579-100579
Open Access | Times Cited: 79
Immunotherapy in glioblastoma treatment: Current state and future prospects
Samuel Luca Rocha Pinheiro, Fabian Fellipe Bueno Lemos, Hanna Santos Marques, et al.
World Journal of Clinical Oncology (2023) Vol. 14, Iss. 4, pp. 138-159
Open Access | Times Cited: 51
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 42
New insight in immunotherapy and combine therapy in colorectal cancer
Kai Ji, Hang Jia, Zixuan Liu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 2
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Natalia Sauer, Wojciech Szlasa, Laura Jonderko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9958-9958
Open Access | Times Cited: 52
Emerging Trends in Immunotherapy for Cancer
Alok Mishra, Amjad Ali, Shubham Dutta, et al.
Diseases (2022) Vol. 10, Iss. 3, pp. 60-60
Open Access | Times Cited: 46
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
Rebecca Ibrahim, Khalil Saleh, Claude Chahine, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1878-1878
Open Access | Times Cited: 24
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Lea Jessica Albrecht, Elisabeth Livingstone, Lisa Zimmer, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 6, pp. 647-657
Open Access | Times Cited: 22
Discovery of First-in-Class Small Molecule Inhibitors of Lymphocyte Activation Gene 3 (LAG-3)
Somaya A. Abdel‐Rahman, Ashfaq Ur Rehman, Moustafa T. Gabr
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 5, pp. 629-635
Open Access | Times Cited: 22
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
Chenyu Lu, Yuanyan Tan
Deleted Journal (2024) Vol. 32, Iss. 1, pp. 200773-200773
Open Access | Times Cited: 15
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Jingjing Su, Yiting Fu, Zitong Cui, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies
Joao Gorgulho, Christoph Roderburg, Fabian Beier, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1013-1022
Open Access | Times Cited: 11
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
Nehal J. Lakhani, Rasha Cosman, Udai Banerji, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102254-102254
Open Access | Times Cited: 8
Fibrinogen: a new player and target on the formation of pre-metastatic niche in tumor metastasis
Yuxin Zhang, Zelin Li, Jiamao Zhang, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 207, pp. 104625-104625
Closed Access | Times Cited: 1
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Paulina Czajka‐Francuz, Maria J. Prendes, Arun K. Mankan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 19
Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
Haihong Jiang, Qinlu Zhang
Oncology Letters (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 7
Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic
Yaser E. Alqurashi
Pathology - Research and Practice (2024) Vol. 254, pp. 155124-155124
Closed Access | Times Cited: 7
LAG‐3 : recent developments in combinational therapies in cancer
Aude Chavanton, Flavie Mialhe, Jimena Abrey, et al.
Cancer Science (2024) Vol. 115, Iss. 8, pp. 2494-2505
Open Access | Times Cited: 6
The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy
Amandine Crombé, Mathtieu Roulleau‐Dugage, Antoîne Italiano
Cancer Communications (2022) Vol. 42, Iss. 12, pp. 1288-1313
Open Access | Times Cited: 23
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil, Maryam Abbaspour
Cancer Communications (2022) Vol. 43, Iss. 2, pp. 177-213
Open Access | Times Cited: 23
Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction
Somaya A. Abdel‐Rahman, Longfei Zhang, Moustafa T. Gabr
SLAS DISCOVERY (2023) Vol. 28, Iss. 4, pp. 188-192
Open Access | Times Cited: 13
Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function
Siyu Wang, Yuxin Wang, Guan Liu, et al.
BMC Medical Genomics (2025) Vol. 18, Iss. 1
Open Access
Ligands for Intestinal Intraepithelial T Lymphocytes in Health and Disease
Akanksha Hada, Zhengguo Xiao
Pathogens (2025) Vol. 14, Iss. 2, pp. 109-109
Open Access
Page 1 - Next Page

Scroll to top